Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · IEX Real-Time Price · USD
71.00
+1.11 (1.59%)
At close: Apr 24, 2024, 4:00 PM
70.80
-0.20 (-0.28%)
After-hours: Apr 24, 2024, 7:15 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for LGND stock have an average target of 116.33, with a low estimate of 95 and a high estimate of 144. The average target predicts an increase of 63.85% from the current stock price of 71.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LGND stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +33.80% | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $144 | Strong Buy | Reiterates | $144 | +102.82% | Feb 29, 2024 |
| Benchmark | Benchmark | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +33.80% | Dec 13, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $144 | Strong Buy | Reiterates | $144 | +102.82% | Sep 19, 2023 |
| Benchmark | Benchmark | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +33.80% | Aug 23, 2023 |
Financial Forecast
Revenue This Year
140.43M
Revenue Next Year
163.94M
from 140.43M
Increased by 16.74%
EPS This Year
4.54
EPS Next Year
5.72
from 4.54
Increased by 25.78%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 148.4M | 178.5M | 247.8M | 274.7M | 357.1M |
| Avg | 140.4M | 163.9M | 225.0M | 266.9M | 346.9M |
| Low | 131.6M | 150.7M | 201.1M | 256.4M | 333.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 27.1% | 51.2% | 22.1% | 33.8% |
| Avg | - | 16.7% | 37.3% | 18.6% | 30.0% |
| Low | - | 7.3% | 22.7% | 13.9% | 24.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 4.78 | 6.22 | 8.01 |
| Avg | 4.54 | 5.72 | 7.78 |
| Low | 4.26 | 5.28 | 7.48 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 36.8% | 40.2% |
| Avg | - | 25.8% | 36.2% |
| Low | - | 16.2% | 30.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.